重庆秋纹生物技术

Chongqing Qiuwen Biotechnology is an innovative biopharmaceutical company based in Chongqing, China, dedicated to the discovery and development of novel small molecule drugs. Founded in 2021, the company primarily focuses on the fields of oncology and immunology, with a specific emphasis on developing inhibitors for challenging targets such as Hematopoietic progenitor kinase 1 (HPK1). Qiuwen Biotechnology leverages its expertise in medicinal chemistry to create first-in-class therapies aimed at modulating the immune system to combat solid tumors. The company's pipeline includes several pre-clinical programs, including its lead candidate QW-001, which are designed to provide superior efficacy and safety profiles. Headquartered in the Liangjiang New Area, Qiuwen Biotechnology is part of the growing life sciences ecosystem in Western China.